Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beni-koji Choleste-Help is a dietary supplement developed and manufactured by Kobayashi Pharmaceutical in Japan. The product is formulated with beni-koji, also known as red yeast rice, which is produced by fermenting rice with the fungus Monascus purpureus. Beni-koji contains monacolin K (chemically identical to lovastatin), a compound known for its cholesterol-lowering properties through inhibition of HMG-CoA reductase, similar to prescription statins[6][7][1]. The supplement was marketed for managing cholesterol levels but was recalled in 2024 after being linked to multiple deaths and over 100 hospitalizations due to acute kidney injury. Investigations revealed contamination with puberulic acid—a nephrotoxic compound produced by Penicillium adametzioides during fermentation—as the likely cause of adverse events[3][4][5]. While traditionally used in East Asian cuisine and medicine, modern supplements like Beni-koji Choleste-Help may contain variable amounts of active compounds and potential contaminants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Beni-koji Choleste-Help.